Peptide name : Polyarginine (R11)

Source/Organism : Not found

Linear/Cyclic : Not found

Chirality : Not found

Peptide length: 11

C-terminal modification: Not found

N-terminal modification : Not found

Non-natural peptide information: None

Assay type : Not specified

Assay time : Not specified

Activity : Not found

Cell line : T24, 5637, RT4

Cancer type : Bladder cancer

Other activity : Not found

Amino acid composition bar chart :

Molecular mass : 1736.058 Dalton

Aliphatic index : 0

Instability index : 529.818

Hydrophobicity (GRAVY) : -4.5

Isoelectric point : 12

Charge (pH 7) : 10.76

Aromaticity : 0

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 0

hydrophobic moment : -0.071

Missing amino acid : W,T,P,I,M,E,K,F,D,N,G,C,H,Q,S,Y,L,A,V

Most occurring amino acid : R

Most occurring amino acid frequency : 11

Least occurring amino acid : R

Least occurring amino acid frequency : 11

Secondary structure fraction (Helix, Turn, Sheet): (0, 0, 0)

SMILES Notation: N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O

1 : Du Y, et al. Novel Application of Cell Penetrating R11 Peptide for Diagnosis of Bladder Cancer. J Biomed Nanotechnol. 2018; 14:161-167. doi: 10.1166/jbn.2018.2499

Paper title : Novel Application of Cell Penetrating R11 Peptide for Diagnosis of Bladder Cancer.

Doi : https://doi.org/10.1166/jbn.2018.2499

Abstract : OBJECTIVE: As a novel cell-permeable peptide, polyarginine (R11) showed great potential as contrast agent to target bladder cancer (BCa) for therapeutic applications. However, its diagnostic ability and uptake efficiency between BCa and normal bladder tissues is unknown. In this study, we investigated the feasibility of R11 conjugated with fluorescein isothiocyanate (FITC-R11) for detecting BCa in clinical practice. METHOD: FITC-R11 was synthesized and incubated with BCa cell lines (T24, 5637, RT4), normal immortalized human bladder epithelial cell line (SVHUC) and clinical specimens from BCa and benign prostate hyperplasia patients. The uptake efficiency was determined by the mean values of relative FITC intensity. Furthermore, FITC-R11 was intravesically injected into the athymic nude mice bearing orthotopic T24-t tumors and pulmonary metastasis of bladder tumor mice models, the fluorescence intensity of bladder tumors and normal bladder tissues was examined, as well as lung tissues. RESULT: After incubation with FITC-R11, the fluorescence intensity of T24, 5637, RT4 and SVHUC cell line was 64678.56 ± 9699.27, 46456.22 ± 2588.06, 33802.02 ± 429.72 and 17785.01 ± 1704.36, respectively (P < 0.05). In the athymic nude mice bearing orthotopic T24-t tumors, FITC-R11 showed elevated accumulation in the bladder tumors compared with normal bladder tissues, FITC-R11 was also accumulated in the lung of pulmonary metastasis mice. Moreover, the uptake efficiency of FITC-R11 in patients' BCa tissues was much higher than in normal bladder tissues (6441.95 vs. 1196.92, P < 0.05), as well as the urine samples of BCa patients and benign prostate hyperplasia patients (30250.37 vs. 4948.42, P < 0.05). CONCLUSION: As compared with normal bladder tissue, FITC-R11 is a more specific molecular probe for BCa, and has the potential application in clinical practice.